Mark T. Iwicki

Companies

• Inhibikase Therapeutics, Inc.Board member Feb 19, 2025 to now¹
• Inhibikase Therapeutics, Inc.Chief executive officer Feb 19, 2025 to now¹
• Q32 Bio Inc.Board member Mar 27, 2024 to now²
• Third Harmonic Bio, Inc.Board member Sep 14, 2022 to now³
• Merus (Netherlands)Board member Jan 2, 2020 to now⁴
• Akero Therapeutics, Inc.Board member Jun 19, 2019 to now⁵
• Kala Pharmaceuticals (United States)Board member Jul 19, 2017 to now⁶
• Kala Pharmaceuticals (United States)Chief executive officer Jul 19, 2017 to Nov 26, 2025⁶
• Jade Biosciences, Inc.Board member Jun 29, 2021 to Jun 7, 2024⁷
• Pulmatrix, Inc.Board member Dec 9, 2015 to Feb 1, 2021⁸
• Aimmune Therapeutics (United Kingdom)Board member Aug 5, 2015 to Oct 14, 2020⁹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• KPKala Pharmaceuticals (United States) KALA103,540 shares¹⁰$19.9K at $0.19Oct 23, 2025
• Merus (Netherlands)0 shares¹¹Dec 12, 2025
• ATAkero Therapeutics, Inc.0 shares¹²Dec 9, 2025
• THThird Harmonic Bio, Inc.0 shares¹³Aug 11, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

• Dec 12, 2025U 73,576 shares at $97.00 of Merus (Netherlands)¹¹
• Dec 9, 2025Returned to company 9,398 shares of Akero Therapeutics, Inc.¹²
• Oct 23, 2025Sold 154,894 shares at $0.81 of Kala Pharmaceuticals (United States)¹⁰
• Aug 11, 2025Other 128,631 shares of Third Harmonic Bio, Inc.¹³
• Jun 24, 2025Sold 13,227 shares at $4.01 of Kala Pharmaceuticals (United States)¹⁴
• Jun 15, 2025Granted 2,450 shares of Kala Pharmaceuticals (United States)¹⁵
• Jun 3, 2025Sold 10,866 shares at $3.74 of Kala Pharmaceuticals (United States)¹⁶
• Jun 3, 2025Sold 10,866 shares at $3.74 of Kala Pharmaceuticals (United States)¹⁷
• Jun 3, 2025Granted 9,398 shares of Akero Therapeutics, Inc.¹⁸
• Jan 6, 2025Sold 5,779 shares at $7.63 of Kala Pharmaceuticals (United States)¹⁹
• Jan 6, 2025Granted 22,100 shares of Kala Pharmaceuticals (United States)¹⁹
• Jun 26, 2024Sold 15,168 shares at $4.75 of Kala Pharmaceuticals (United States)²⁰
• May 31, 2024Sold 7,392 shares at $6.09 of Kala Pharmaceuticals (United States)²¹
• Jan 4, 2024Sold 4,539 shares at $6.73 of Kala Pharmaceuticals (United States)²²
• Jan 4, 2024Granted 14,300 shares of Kala Pharmaceuticals (United States)²²
• Jun 22, 2023Granted 158,873 shares of Kala Pharmaceuticals (United States)²³
• May 31, 2023Granted 71,715 shares of Kala Pharmaceuticals (United States)²⁴
• Apr 14, 2023Exercised options 36,632 shares at $7.97 of Merus (Netherlands)²⁵
• Apr 14, 2023Exercised options 36,944 shares at $6.57 of Merus (Netherlands)²⁵
• Jan 4, 2023Sold 198 shares at $28.54 of Kala Pharmaceuticals (United States)²⁶
• Jan 4, 2023Granted 41,700 shares of Kala Pharmaceuticals (United States)²⁶
• Oct 26, 2022Sold 561 shares at $6.52 of Kala Pharmaceuticals (United States)²⁷
• Jun 27, 2022Sold 7,975 shares at $0.37 of Kala Pharmaceuticals (United States)²⁸
• Jan 4, 2022Sold 9,518 shares at $1.30 of Kala Pharmaceuticals (United States)²⁹
• Oct 26, 2021Sold 27,598 shares at $1.80 of Kala Pharmaceuticals (United States)³⁰